FDC
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
F D C Approves Expansion Of Liquid Oral Facility At Sinnar Plant
April 30 (Reuters) - F D C Ltd FDC.NS:
F D C LTD - APPROVES EXPANSION OF LIQUID ORAL FACILITY AT SINNAR PLANT
F D C LTD - PROPOSED CAPACITY EXPANSION TO 77,000 KILOLITRES PER ANNUM
F D C LTD - INVESTMENT REQUIRED FOR EXPANSION APPROXIMATELY 1.40 BILLION RUPEES
Source text: ID:nBSE6dqq7c
Further company coverage: FDC.NS
(([email protected];;))
April 30 (Reuters) - F D C Ltd FDC.NS:
F D C LTD - APPROVES EXPANSION OF LIQUID ORAL FACILITY AT SINNAR PLANT
F D C LTD - PROPOSED CAPACITY EXPANSION TO 77,000 KILOLITRES PER ANNUM
F D C LTD - INVESTMENT REQUIRED FOR EXPANSION APPROXIMATELY 1.40 BILLION RUPEES
Source text: ID:nBSE6dqq7c
Further company coverage: FDC.NS
(([email protected];;))
F D C Gets Order Imposing Tax, Penalty 5.7 Million Rupees Each
Feb 19 (Reuters) - F D C Ltd FDC.NS:
F D C - GOT ORDER IMPOSING TAX, PENALTY 5.7 MILLION RUPEES EACH
Source text: ID:nBSE8Mxmw3
Further company coverage: FDC.NS
(([email protected];;))
Feb 19 (Reuters) - F D C Ltd FDC.NS:
F D C - GOT ORDER IMPOSING TAX, PENALTY 5.7 MILLION RUPEES EACH
Source text: ID:nBSE8Mxmw3
Further company coverage: FDC.NS
(([email protected];;))
F D C Gets Tax Demand Order For For 66.9 Million Rupees, Interest Of 52.1 Million Rupees
Jan 31 (Reuters) - F D C Ltd FDC.NS:
F D C - GOT TAX DEMAND ORDER FOR FOR 66.9 MILLION RUPEES, INTEREST OF 52.1 MILLION RUPEES
Source text: ID:nBSE9s9226
Further company coverage: FDC.NS
(([email protected];;))
Jan 31 (Reuters) - F D C Ltd FDC.NS:
F D C - GOT TAX DEMAND ORDER FOR FOR 66.9 MILLION RUPEES, INTEREST OF 52.1 MILLION RUPEES
Source text: ID:nBSE9s9226
Further company coverage: FDC.NS
(([email protected];;))
F D C Receives US FDA Approval For Cefixime 400 Mg Tablets
Dec 18 (Reuters) - F D C Ltd FDC.NS:
RECEIVES US FDA APPROVAL FOR CEFIXIME 400 MG TABLETS
Source text: ID:nBSE7Qd8Mh
Further company coverage: FDC.NS
(([email protected];;))
Dec 18 (Reuters) - F D C Ltd FDC.NS:
RECEIVES US FDA APPROVAL FOR CEFIXIME 400 MG TABLETS
Source text: ID:nBSE7Qd8Mh
Further company coverage: FDC.NS
(([email protected];;))
F D C Got Establishment Inspection Report From USFDA With No Observations For Baddi Facility
Nov 13 (Reuters) - F D C Ltd FDC.NS:
GOT ESTABLISHMENT INSPECTION REPORT FROM US FDA WITH NO OBSERVATIONS FOR BADDI FACILITY
Further company coverage: FDC.NS
(([email protected];))
Nov 13 (Reuters) - F D C Ltd FDC.NS:
GOT ESTABLISHMENT INSPECTION REPORT FROM US FDA WITH NO OBSERVATIONS FOR BADDI FACILITY
Further company coverage: FDC.NS
(([email protected];))
FDC Sept-Quarter Consol Net Profit At 720.4 Million Rupees
Nov 6 (Reuters) - F D C Ltd FDC.NS:
F D C SEPT-QUARTER CONSOL NET PROFIT 720.4 MILLION RUPEES
F D C SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 5.14 BILLION RUPEES
F D C LTD - DIVIDEND 5 RUPEES PER SHARE
Source text: ID:nNSEbz8gXg
Further company coverage: FDC.NS
(([email protected];))
Nov 6 (Reuters) - F D C Ltd FDC.NS:
F D C SEPT-QUARTER CONSOL NET PROFIT 720.4 MILLION RUPEES
F D C SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 5.14 BILLION RUPEES
F D C LTD - DIVIDEND 5 RUPEES PER SHARE
Source text: ID:nNSEbz8gXg
Further company coverage: FDC.NS
(([email protected];))
F D C June-Quarter Consol Net Profit 1.19 Billion Rupees
Aug 7 (Reuters) - F D C Ltd FDC.NS:
F D C JUNE-QUARTER CONSOL NET PROFIT 1.19 BILLION RUPEES
F D C JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 6.38 BILLION RUPEES
Further company coverage: FDC.NS
(([email protected];))
Aug 7 (Reuters) - F D C Ltd FDC.NS:
F D C JUNE-QUARTER CONSOL NET PROFIT 1.19 BILLION RUPEES
F D C JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 6.38 BILLION RUPEES
Further company coverage: FDC.NS
(([email protected];))
India's FDC hits record high after Q3 profit surge
** Shares of FDC FDC.NS up as much as 9% to a record high of 471.95 rupees after Dec-quarter results
** Pharma and consumer healthcare firm says Q3 consolidated net profit surges 94.5%, revenue from operations up 11.9%
** Stock on track for fourth straight session of gains, which will be its longest winning streak in two months
** FDC up 17.6% YTD vs 3.5% gain in Nifty 500 index .NIFTY500
(Reporting by Rama Venkat in Bengaluru)
** Shares of FDC FDC.NS up as much as 9% to a record high of 471.95 rupees after Dec-quarter results
** Pharma and consumer healthcare firm says Q3 consolidated net profit surges 94.5%, revenue from operations up 11.9%
** Stock on track for fourth straight session of gains, which will be its longest winning streak in two months
** FDC up 17.6% YTD vs 3.5% gain in Nifty 500 index .NIFTY500
(Reporting by Rama Venkat in Bengaluru)
India's FDC hits all-time high in heavy volume
** Shares of drug maker FDC Ltd FDC.NS rise as much as 8.6% to record high of 432.80 rupees in heavy volume
** Reuters could not immediately verify the reason for the move
** Over 3.2 mln shares traded; stock's busiest session since Aug. 10, 2023, a day after FDC's Q1 results, share buyback plan
** Stock last up nearly 5%; It has risen 5% or more only on six occasions in 2023
** Stock rose ~46% in 2023, outperforming Nifty Pharma .NIPHARM index's ~34% rise
(Reporting by Nandan Mandayam in Bengaluru)
(([email protected]; Mobile: +91 9591011727;))
** Shares of drug maker FDC Ltd FDC.NS rise as much as 8.6% to record high of 432.80 rupees in heavy volume
** Reuters could not immediately verify the reason for the move
** Over 3.2 mln shares traded; stock's busiest session since Aug. 10, 2023, a day after FDC's Q1 results, share buyback plan
** Stock last up nearly 5%; It has risen 5% or more only on six occasions in 2023
** Stock rose ~46% in 2023, outperforming Nifty Pharma .NIPHARM index's ~34% rise
(Reporting by Nandan Mandayam in Bengaluru)
(([email protected]; Mobile: +91 9591011727;))
India pharma sector growth slows in November on lower volumes
** India's pharmaceutical sector growth slowed to 2.9% year-on-year in November from 13.7% in October as volumes drop, data from All India Origin Chemists and Distributors (AIOCD) showed
** Volumes in November down 4.5% year-on-year after rising 5% in the previous month
** Dermatology and opthalmology segments witness fall in sales while anti-infectives, cardiac, respiratory segments see rise in sales in November
** Eris Lifesciences ERIS.NS, Cipla CIPL.NS, Torrent Pharmaceuticals TORP.NS, Sun Pharmaceutical Industries SUN.NS and Glenmark Pharmaceuticals GLEN.NS see sales uptick of 7% to 11%, outperforming the Indian pharma market
** FDC FDC.NS, Alembic Pharma ALEM.NS, GlaxoSmithKline Pharmaceuticals GLAX.NS and Mankind Pharma MNKI.NS underperform the industry, in terms of November sales
** Pfizer PFIZ.NS sees sales decline of 11.9% while Sanofi India SANO.NS posts 5.7% monthly sales drop
** Nifty pharma index .NIPHARM down 0.9% on the day, dragged by 5% drop in Dr. Reddy's Laboratories REDY.NS on U.S. drug regulator's observations on the drug maker's facility at Hyderabad
** Pharma index up 27% in 2023 so far, compared with 16% rise in Nifty 50 index .NSEI
Indian pharma market growth slows in November https://tmsnrt.rs/3t4SknU
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463;))
** India's pharmaceutical sector growth slowed to 2.9% year-on-year in November from 13.7% in October as volumes drop, data from All India Origin Chemists and Distributors (AIOCD) showed
** Volumes in November down 4.5% year-on-year after rising 5% in the previous month
** Dermatology and opthalmology segments witness fall in sales while anti-infectives, cardiac, respiratory segments see rise in sales in November
** Eris Lifesciences ERIS.NS, Cipla CIPL.NS, Torrent Pharmaceuticals TORP.NS, Sun Pharmaceutical Industries SUN.NS and Glenmark Pharmaceuticals GLEN.NS see sales uptick of 7% to 11%, outperforming the Indian pharma market
** FDC FDC.NS, Alembic Pharma ALEM.NS, GlaxoSmithKline Pharmaceuticals GLAX.NS and Mankind Pharma MNKI.NS underperform the industry, in terms of November sales
** Pfizer PFIZ.NS sees sales decline of 11.9% while Sanofi India SANO.NS posts 5.7% monthly sales drop
** Nifty pharma index .NIPHARM down 0.9% on the day, dragged by 5% drop in Dr. Reddy's Laboratories REDY.NS on U.S. drug regulator's observations on the drug maker's facility at Hyderabad
** Pharma index up 27% in 2023 so far, compared with 16% rise in Nifty 50 index .NSEI
Indian pharma market growth slows in November https://tmsnrt.rs/3t4SknU
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463;))
India's F D C Ltd Sept-Quarter Consol Net Profit Rises
Nov 8 (Reuters) - F D C Ltd FDC.NS:
INDIA'S F D C LTD SEPT-QUARTER CONSOL NET PROFIT 698.2 MILLION RUPEES VERSUS PROFIT 518.4 MILLION RUPEES
F D C LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 4.86 BILLION RUPEES VERSUS 4.45 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: FDC.NS
(([email protected];))
Nov 8 (Reuters) - F D C Ltd FDC.NS:
INDIA'S F D C LTD SEPT-QUARTER CONSOL NET PROFIT 698.2 MILLION RUPEES VERSUS PROFIT 518.4 MILLION RUPEES
F D C LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 4.86 BILLION RUPEES VERSUS 4.45 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: FDC.NS
(([email protected];))
Carrefour sticks price warnings on food to shame suppliers
By Dominique Vidalon
PARIS, Sept 14 (Reuters) - French supermarket chain Carrefour CARR.PA has slapped price warnings on products from Lindt chocolates to Lipton Ice Tea to pressure top consumer goods suppliers Nestle, PepsiCo and Unilever to reduce inflation ahead of much-anticipated contract talks.
Carrefour is putting stickers on products that have shrunk in size but cost more even after raw materials prices have eased, to rally consumer support as retailers prepare to face the world's biggest brands in negotiations due to start soon and end by Oct. 15.
"Obviously, the aim in stigmatising these products is to be able to tell manufacturers to rethink their pricing policy," Stefen Bompais, director of client communications at Carrefour, said in an interview.
Carrefour CEO Alexandre Bompard, who also heads retail industry lobby group FDC, has repeatedly said consumer goods companies are not cooperating in efforts to cut the price of thousands of staples despite a fall in the cost of raw materials.
In this he is being backed by Finance Minister Bruno Le Maire, who in June summoned 75 big retailers and consumer groups to his ministry urging them to cut prices. After a new round of meetings last month, Le Maire said Unilever, Nestle and PepsiCo were among companies not toeing the line on prices.
Since Monday, Carrefour has marked 26 products in its stores in France with labels reading, "This product has seen its volume or weight fall and the effective price by the supplier rise."
For example, Carrefour said a bottle of sugar-free peach-flavoured Lipton Ice Tea, produced by PepsiCo, shrank to 1.25 litres (0.33 gallon) from 1.5 litres, resulting in a 40% effective increase in the price per litre.
Guigoz infant formula produced by Nestle went from 900 grams (31.75 oz) to 830 grams, while a Viennetta ice-cream cake, produced by Unilever, shrank to 320 grams from 350 grams previously.
Lindt and PepsiCo did not respond to a request for comment. Nestle and Unilever declined to comment.
Consumer groups say "shrinkflation" is a widespread practice, which supermarkets like Carrefour are also guilty of in their private label products.
France, like other European countries, has been trying for months to ease consumer pain in the face of a surge in the cost of living, strong-arming big business to freeze or cut food and transport prices - with mixed results so far.
But Carrefour's move to name and shame suppliers marks an escalation in the war of words between retailers and big multinationals.
The shrinkflation warnings are in all French Carrefour stores, and will last until the targeted suppliers agree to price cuts, Bompais said. The retailer could extend the warnings to other goods, but does not plan to extend the initiative to other countries.
Le Maire said last month consumer goods companies and retailers had agreed to bring forward annual price negotiations - which would normally have taken place next year - to September. The talks will result in price cuts from January, he said.
(Reporting by Dominique Vidalon in Paris, Richa Naidu in London; Writing by Helen Reid; Editing by Silvia Aloisi and Richard Chang)
(([email protected]; +44 7584 155 200 ;))
By Dominique Vidalon
PARIS, Sept 14 (Reuters) - French supermarket chain Carrefour CARR.PA has slapped price warnings on products from Lindt chocolates to Lipton Ice Tea to pressure top consumer goods suppliers Nestle, PepsiCo and Unilever to reduce inflation ahead of much-anticipated contract talks.
Carrefour is putting stickers on products that have shrunk in size but cost more even after raw materials prices have eased, to rally consumer support as retailers prepare to face the world's biggest brands in negotiations due to start soon and end by Oct. 15.
"Obviously, the aim in stigmatising these products is to be able to tell manufacturers to rethink their pricing policy," Stefen Bompais, director of client communications at Carrefour, said in an interview.
Carrefour CEO Alexandre Bompard, who also heads retail industry lobby group FDC, has repeatedly said consumer goods companies are not cooperating in efforts to cut the price of thousands of staples despite a fall in the cost of raw materials.
In this he is being backed by Finance Minister Bruno Le Maire, who in June summoned 75 big retailers and consumer groups to his ministry urging them to cut prices. After a new round of meetings last month, Le Maire said Unilever, Nestle and PepsiCo were among companies not toeing the line on prices.
Since Monday, Carrefour has marked 26 products in its stores in France with labels reading, "This product has seen its volume or weight fall and the effective price by the supplier rise."
For example, Carrefour said a bottle of sugar-free peach-flavoured Lipton Ice Tea, produced by PepsiCo, shrank to 1.25 litres (0.33 gallon) from 1.5 litres, resulting in a 40% effective increase in the price per litre.
Guigoz infant formula produced by Nestle went from 900 grams (31.75 oz) to 830 grams, while a Viennetta ice-cream cake, produced by Unilever, shrank to 320 grams from 350 grams previously.
Lindt and PepsiCo did not respond to a request for comment. Nestle and Unilever declined to comment.
Consumer groups say "shrinkflation" is a widespread practice, which supermarkets like Carrefour are also guilty of in their private label products.
France, like other European countries, has been trying for months to ease consumer pain in the face of a surge in the cost of living, strong-arming big business to freeze or cut food and transport prices - with mixed results so far.
But Carrefour's move to name and shame suppliers marks an escalation in the war of words between retailers and big multinationals.
The shrinkflation warnings are in all French Carrefour stores, and will last until the targeted suppliers agree to price cuts, Bompais said. The retailer could extend the warnings to other goods, but does not plan to extend the initiative to other countries.
Le Maire said last month consumer goods companies and retailers had agreed to bring forward annual price negotiations - which would normally have taken place next year - to September. The talks will result in price cuts from January, he said.
(Reporting by Dominique Vidalon in Paris, Richa Naidu in London; Writing by Helen Reid; Editing by Silvia Aloisi and Richard Chang)
(([email protected]; +44 7584 155 200 ;))
India's FDC hits record high as Q1 profit jumps 55%
** Shares of FDC Ltd FDC.NS rise as much as 10.2% to a record high of 429 rupees
** Co on Wednesday reported its consolidated net profit jumped 55.3% to 1.1 bln rupees ($13.28 mln), rev from ops up 8.3% Y/Y
** Adds, approved acquisition of additional 7% stake in unit FDC SA; also approved buyback for up to 3.1 mln shares at 500 rupees apiece
** More than 2.4 mln shares change hands by 09:55 a.m. IST vs 3.8x 30-day avg of 639,891 shares
** Analysts covering the stock on average have a "strong buy" rating; median PT is 350 rupees - Refinitiv data
** Stock up 43.7% YTD up to last close
($1 = 82.8200 Indian rupees)
(Reporting by Ashna Teresa Britto in Bengaluru)
(([email protected] ; ( +91 8078332441))
** Shares of FDC Ltd FDC.NS rise as much as 10.2% to a record high of 429 rupees
** Co on Wednesday reported its consolidated net profit jumped 55.3% to 1.1 bln rupees ($13.28 mln), rev from ops up 8.3% Y/Y
** Adds, approved acquisition of additional 7% stake in unit FDC SA; also approved buyback for up to 3.1 mln shares at 500 rupees apiece
** More than 2.4 mln shares change hands by 09:55 a.m. IST vs 3.8x 30-day avg of 639,891 shares
** Analysts covering the stock on average have a "strong buy" rating; median PT is 350 rupees - Refinitiv data
** Stock up 43.7% YTD up to last close
($1 = 82.8200 Indian rupees)
(Reporting by Ashna Teresa Britto in Bengaluru)
(([email protected] ; ( +91 8078332441))
India's F D C Ltd June-Qtr Consol Net Profit Rises
Aug 9 (Reuters) - F D C Ltd FDC.NS:
F D C LTD - RE-APPOINTS MOHAN A. CHANDAVARKAR AS MD
F D C LTD - RE-APPOINTS NANDAN M. CHANDAVARKAR AS JOINT MD
INDIA'S F D C LTD JUNE-QUARTER CONSOL NET PROFIT 1.1 BILLION RUPEES VERSUS PROFIT 707.4 MILLION RUPEES
F D C LTD JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 5.36 BILLION RUPEES VERSUS 4.95 BILLION RUPEES
Source text for Eikon: ID:nBSE6yBhQC
Further company coverage: FDC.NS
(([email protected];))
Aug 9 (Reuters) - F D C Ltd FDC.NS:
F D C LTD - RE-APPOINTS MOHAN A. CHANDAVARKAR AS MD
F D C LTD - RE-APPOINTS NANDAN M. CHANDAVARKAR AS JOINT MD
INDIA'S F D C LTD JUNE-QUARTER CONSOL NET PROFIT 1.1 BILLION RUPEES VERSUS PROFIT 707.4 MILLION RUPEES
F D C LTD JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 5.36 BILLION RUPEES VERSUS 4.95 BILLION RUPEES
Source text for Eikon: ID:nBSE6yBhQC
Further company coverage: FDC.NS
(([email protected];))
India's FDC hits 2-year high on proposal for share buyback
** Shares of FDC FDC.NS rise as much as 10.32% to a two-year high of 378.40 rupees
** Uptick after the pharmaceutical ingredients maker says it will consider proposal for buyback of shares in its board meeting on August 9
** FDC to also report its June-quarter earnings on August 9
** Stock most active in nearly two months with a trading volume of 4.64 mln shares, 11x the 30-day avg - Refinitiv data
** Relative strength index rises above 70 on Thursday, suggesting the stock may be overbought - Refinitiv data
** Stock up 36.90% in 2023 so far, including today's gains compared to 7% rise in Nifty 50 index .NSEI
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463))
** Shares of FDC FDC.NS rise as much as 10.32% to a two-year high of 378.40 rupees
** Uptick after the pharmaceutical ingredients maker says it will consider proposal for buyback of shares in its board meeting on August 9
** FDC to also report its June-quarter earnings on August 9
** Stock most active in nearly two months with a trading volume of 4.64 mln shares, 11x the 30-day avg - Refinitiv data
** Relative strength index rises above 70 on Thursday, suggesting the stock may be overbought - Refinitiv data
** Stock up 36.90% in 2023 so far, including today's gains compared to 7% rise in Nifty 50 index .NSEI
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463))
F D C Ltd- Got EIR From FDA Inspection At Waluj, Aurangabad Facility
June 15 (Reuters) - F D C Ltd FDC.NS:
F D C LTD- FDA INSPECTION AT COMPANY'S MANUFACTURING FACILITY LOCATED AT WALUJ, AURANGABAD
F D C LTD- RECEIPT OF ESTABLISHMENT INSPECTION REPORT (EIR) WITH NO ACTION INDICATED
Source text for Eikon: ID:nBSE4j7NPX
Further company coverage: FDC.NS
(([email protected];))
June 15 (Reuters) - F D C Ltd FDC.NS:
F D C LTD- FDA INSPECTION AT COMPANY'S MANUFACTURING FACILITY LOCATED AT WALUJ, AURANGABAD
F D C LTD- RECEIPT OF ESTABLISHMENT INSPECTION REPORT (EIR) WITH NO ACTION INDICATED
Source text for Eikon: ID:nBSE4j7NPX
Further company coverage: FDC.NS
(([email protected];))
India's F D C March-Quarter Consol Net Profit Rises
May 25 (Reuters) - F D C Ltd FDC.NS:
MARCH-QUARTER CONSOL NET PROFIT 307.1 MILLION RUPEES VERSUS 104.4 MILLION RUPEES
MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 4.35 BILLION RUPEES VERSUS 3.41 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: FDC.NS
(([email protected];))
May 25 (Reuters) - F D C Ltd FDC.NS:
MARCH-QUARTER CONSOL NET PROFIT 307.1 MILLION RUPEES VERSUS 104.4 MILLION RUPEES
MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 4.35 BILLION RUPEES VERSUS 3.41 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: FDC.NS
(([email protected];))
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does FDC do?
FDC Limited is a renowned pharmaceutical company in India, established in 1936. It focuses on producing top-notch products such as Oral Rehydration Salts (ORS) and prescription formulations with internationally accredited manufacturing units.
Who are the competitors of FDC?
FDC major competitors are Strides Pharma Scien, Procter&Gamble Healt, Sequent Scientific, Unichem Lab, Gufic Biosciences, Orchid Pharma, Guj. Themis Biosyn. Market Cap of FDC is ₹6,991 Crs. While the median market cap of its peers are ₹4,173 Crs.
Is FDC financially stable compared to its competitors?
FDC seems to be less financially stable compared to its competitors. Altman Z score of FDC is 5.37 and is ranked 4 out of its 8 competitors.
Does FDC pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. FDC latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has FDC allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is FDC balance sheet?
Balance sheet of FDC is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of FDC improving?
The profit is oscillating. The profit of FDC is ₹267 Crs for TTM, ₹305 Crs for Mar 2024 and ₹194 Crs for Mar 2023.
Is the debt of FDC increasing or decreasing?
The net debt of FDC is decreasing. Latest net debt of FDC is -₹52.66 Crs as of Mar-25. This is less than Mar-24 when it was -₹52.14 Crs.
Is FDC stock expensive?
Yes, FDC is expensive. Latest PE of FDC is 26.2, while 3 year average PE is 23.14. Also latest EV/EBITDA of FDC is 21.86 while 3yr average is 20.29.
Has the share price of FDC grown faster than its competition?
FDC has given lower returns compared to its competitors. FDC has grown at ~11.29% over the last 10yrs while peers have grown at a median rate of 21.67%
Is the promoter bullish about FDC?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in FDC is 69.66% and last quarter promoter holding is 69.66%.
Are mutual funds buying/selling FDC?
The mutual fund holding of FDC is increasing. The current mutual fund holding in FDC is 6.18% while previous quarter holding is 5.87%.